Finance
Results: 39073-39084 of 42191

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

LUCARA ANNOUNCES Q3 2023 RESULTS; STRONG REVENUE SUPPORTS CONTINUED DEVELOPMENT OF THE UNDERGROUND EXPANSION







